ORION Biotech Catalyst Calendar
Menu

Free biotech catalyst calendar

Each date comes with the SEC sentence it came from. Open a line to see the sentence and how its wording has changed.Each date comes with its SEC sentence.

All stages · All sizes · All periods

Filters

Stage
Event type
Company size (public float)
Period

Optional; keeps the company’s stated period precision.

250 programs as of

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

Window ends in: Q1 2027

Grouped by the period end. The company's wording is retained in each row; no countdown is shown.

  1. DYNDyne Therapeutics · z-basivarsenTopline/data readout MatchedSEC ↗Watch

    Period the company stated: Q1 2027

    to expect topline data in Q1 2027 from the ACHIEVE registrational expansion cohort (REC)Details

    Dyne Therapeutics, Inc. (DYN) · z-basivarsen

    Stage: OtherSEC filing · “Phase 1/2”

    Public float (as of ): $948M (SEC filing) · $500M–$2B

    Period the company stated: Q1 2027

    Dyne continues to expect topline data in Q1 2027 from the ACHIEVE registrational expansion cohort (REC)

    ClinicalTrials.gov NCT05481879 · NCT stated in SEC filing

    SEC Form EX-99.1 · Filed: · Accession: 0001818794-26-000009 · Last checked: · Matched

    Earlier SEC statements (3)
    1. · “Topline data from the ACHIEVE REC are planned for Q1 2027” · SEC filing
    2. · “topline data planned for Q1 2027” · SEC filing
    3. · “data from the ACHIEVE REC are planned for Q1 2027” · SEC filing
  2. MBRXMoleculin Biotech · Annamycin / naxtarubicin + cytarabineTopline/data readout MatchedSEC ↗Watch

    Period the company stated: Q1 2027

    track for a comprehensive Q1 2027 readoutDetails

    Moleculin Biotech, Inc. (MBRX) · Annamycin / naxtarubicin + cytarabine

    Stage: OtherSEC filing · “Phase 2/3”

    Public float (as of ): $8M (SEC filing) · Under $500M

    Period the company stated: Q1 2027

    the trial on track for a comprehensive Q1 2027 readout

    ClinicalTrials.gov NCT06788756 · NCT stated in SEC filing

    SEC Form 8-K · Filed: · Accession: 0001437749-26-031419 · Last checked: · Matched

    Earlier SEC statements (2)
    1. · “Enrollment remains on track to reach the 90-patient milestone in September with the data readout in the December 2026 to February 2027 timeframe.” · SEC filing
    2. · “The Company expects to reach final recruitment and treatment of the 90 subjects in Part A in September and the final readout in the December 2026 to February 2027 timeframe.” · SEC filing
  3. OCGNOcugen · OCU400Topline/data readout MatchedSEC ↗Watch

    Period the company stated: 1Q 2027

    readout expected in 1Q 2027 and BLA submission to follow.Details

    Ocugen, Inc. (OCGN) · OCU400

    Stage: Phase 3SEC filing · “Phase 3”

    Public float (as of ): $279M (SEC filing) · Under $500M

    Period the company stated: 1Q 2027

    Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical development with a topline readout expected in 1Q 2027 and BLA submission to follow.

    SEC Form 8-K · Filed: · Accession: 0001104659-26-082897 · Last checked: · Matched

  4. SEPNSepterna · SEP-479Topline/data readout MatchedSEC ↗Watch

    Period the company stated: Q1 2027

    SAD / MAD Data Expected in Q1 2027Details

    Septerna, Inc. (SEPN) · SEP-479

    Stage: Not stated

    Public float (as of ): $363M (SEC filing) · Under $500M

    Period the company stated: Q1 2027

    SAD / MAD Data Expected in Q1 2027

    SEC Form 8-K · Filed: · Accession: 0001193125-26-342328 · Last checked: · Matched

    Earlier SEC statements (4)
    1. · “We anticipate reporting data from the trial in late 2026 or early 2027.” · SEC filing
    2. · “data expected in late 2026 or early 2027.” · SEC filing
    3. · “Septerna anticipates reporting data from the trial in late 2026 or early 2027.” · SEC filing
    4. · “We anticipate announcing topline data from this Phase 1 clinical trial around the end of 2026 or early 2027.” · SEC filing
  5. SRPTSarepta Therapeutics · ELEVIDYSTopline/data readout MatchedSEC ↗Watch

    Period the company stated: Q1 2027

    from the full cohort in Q1 2027.Details

    Sarepta Therapeutics, Inc. (SRPT) · ELEVIDYS

    Stage: Not stated

    Public float (as of ): $1.6B (SEC filing) · $500M–$2B

    Period the company stated: Q1 2027

    12-week data from the full cohort in Q1 2027.

    SEC Form 8-K · Filed: · Accession: 0001193125-26-335056 · Last checked: · Matched

  6. STOKStoke Therapeutics · zorevunersenNDA/BLA submission MatchedSEC ↗Watch

    Period the company stated: Q1 2027

    planned to initiate in Q1 2027Details

    Stoke Therapeutics, Inc. (STOK) · zorevunersen

    Stage: Phase 3SEC filing · “Phase 3”

    Public float (as of ): $592M (SEC filing) · $500M–$2B

    Period the company stated: Q1 2027

    rolling U.S. NDA submission planned to initiate in Q1 2027

    ClinicalTrials.gov NCT06872125 · NCT stated in SEC filing

    SEC Form 8-K · Filed: · Accession: 0001193125-26-330537 · Last checked: · Matched

  7. TCRXTScan Therapeutics · PRAME/MAGE-A4 in vivo-engineered TCR-T candidatesTopline/data readout MatchedSEC ↗Watch

    Period the company stated: Q1 2027

    share preclinical data in Q1 2027Details

    TScan Therapeutics, Inc. (TCRX) · PRAME/MAGE-A4 in vivo-engineered TCR-T candidates

    Stage: OtherSEC filing · “preclinical”

    Public float (as of ): $56M (SEC filing) · Under $500M

    Period the company stated: Q1 2027

    The Company expects to share preclinical data in Q1 2027

    SEC Form 8-K · Filed: · Accession: 0001193125-26-379343 · Last checked: · Matched

  8. VERUVeru · enobosarm + semaglutideTopline/data readout MatchedSEC ↗Watch

    Period the company stated: Q1 2027

    on track for calendar Q1 2027Details

    VERU INC. (VERU) · enobosarm + semaglutide

    Stage: Phase 2SEC filing · “Phase 2b”

    Public float (as of ): $64M (SEC filing) · Under $500M

    Period the company stated: Q1 2027

    Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027

    SEC Form 8-K · Filed: · Accession: 0001193125-26-341187 · Last checked: · Matched

    Earlier SEC statements (2)
    1. · “results of the interim analysis which is expected in Q1 calendar year 2027” · SEC filing
    2. · “interim analysis results anticipated Q1 calendar year 2027” · SEC filing
  9. VRDNViridian Therapeutics · elegrobartNDA/BLA submission MatchedSEC ↗Watch

    Period the company stated: Q1 2027

    the FDA for elegrobart in Q1 2027.Details

    Viridian Therapeutics, Inc.\DE (VRDN) · elegrobart

    Stage: Not stated

    Public float (as of ): $943M (SEC filing) · $500M–$2B

    Period the company stated: Q1 2027

    Viridian is on track to submit a Biologics License Application (BLA) to the FDA for elegrobart in Q1 2027.

    SEC Form 8-K · Filed: · Accession: 0001193125-26-336691 · Last checked: · Matched

    Earlier SEC statements (7)
    1. · “Elegrobart BLA Submission Expected in Q1 2027” · SEC filing
    2. · “Viridian plans to submit a BLA to the FDA in Q1 2027” · SEC filing
    3. · “we anticipate submitting a BLA for VRDN-003 for the treatment of TED by the end of 2026.” · SEC filing
    4. · “we anticipate submitting a BLA for VRDN-003 for the treatment of TED by the end of 2026.” · SEC filing
    5. · “we anticipate submitting a BLA for VRDN-003 for the treatment of TED by the end of 2026.” · SEC filing
    6. · “we anticipate submitting a BLA for VRDN-003 for the treatment of TED by the end of 2026.” · SEC filing
    7. · “we anticipate submitting a BLA for VRDN-003 for the treatment of TED by the end of 2026.” · SEC filing

Window ends in: Q2 2027

Grouped by the period end. The company's wording is retained in each row; no countdown is shown.

  1. AVIRAtea Pharmaceuticals · bemnifosbuvir + ruzasvirNDA/BLA submission MatchedSEC ↗Watch

    Period the company stated: second quarter of 2027

    (FDA) in the second quarter of 2027.Details

    Atea Pharmaceuticals, Inc. (AVIR) · bemnifosbuvir + ruzasvir

    Stage: Phase 3SEC filing · “Phase 3”

    Public float (as of ): $262M (SEC filing) · Under $500M

    Period the company stated: second quarter of 2027

    Following the recent topline readout for C-BEYOND and pending results from C-FORWARD, Atea anticipates submitting a new drug application (NDA) to the US Food & Drug Administration (FDA) in the second quarter of 2027.

    ClinicalTrials.gov NCT06868264 · NCT stated in SEC filing

    ClinicalTrials.gov NCT07037277 · NCT stated in SEC filing

    SEC Form 8-K · Filed: · Accession: 0001193125-26-346888 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “we currently anticipate submitting an NDA to the FDA in March 2027” · SEC filing
  2. CNTXContext Therapeutics · CTIM-76Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second quarter of 2027

    CTIM-76 Q3W trial in the second quarter of 2027.Details

    Context Therapeutics Inc. (CNTX) · CTIM-76

    Stage: Phase 1SEC filing · “Phase 1a”

    Public float (as of ): $57M (SEC filing) · Under $500M

    Period the company stated: second quarter of 2027

    We expect to share initial Phase 1a data for our CTIM-76 Q3W trial in the second quarter of 2027.

    SEC Form 10-Q · Filed: · Accession: 0001628280-26-053347 · Last checked: · Matched

  3. JSPRJasper Therapeutics · KP-104 (vensobafusp alfa)Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second quarter of 2027

    and updated data in the second quarter of 2027Details

    Jasper Therapeutics, Inc. (JSPR) · KP-104 (vensobafusp alfa)

    Stage: Phase 2SEC filing · “Phase 2”

    Public float (as of ): $74M (SEC filing) · Under $500M

    Period the company stated: second quarter of 2027

    We expect to report interim data from Stage 1 of the ongoing Phase 2 basket trial in the fourth quarter of 2026 and updated data in the second quarter of 2027

    SEC Form 10-Q · Filed: · Accession: 0001213900-26-089592 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “The Combined Company expects to report interim data from Stage 1 of the ongoing Phase 2 basket trial in rare renal indications in the fourth quarter of 2026, and updated data in the second quarter of 2027.” · SEC filing
  4. JSPRJasper Therapeutics · KP-104 (vensobafusp alfa)Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second quarter of 2027

    2 of the study in the second quarter of 2027.Details

    Jasper Therapeutics, Inc. (JSPR) · KP-104 (vensobafusp alfa)

    Stage: Not stated

    Public float (as of ): $74M (SEC filing) · Under $500M

    Period the company stated: second quarter of 2027

    we plan to report interim data from Stage 2 of the study in the second quarter of 2027.

    SEC Form 10-Q · Filed: · Accession: 0001213900-26-089592 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “Additionally, the Combined Company plans to report interim data from Stage 2 of the study in the second quarter of 2027.” · SEC filing
  5. MGTXMeiraGTx Holdings · AAV2-hAQP1Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second quarter of 2027

    data readout in the second quarter of 2027Details

    MeiraGTx Holdings plc (MGTX) · AAV2-hAQP1

    Stage: Phase 2SEC filing · “Phase 2”

    Public float (as of ): $524M (SEC filing) · $500M–$2B

    Period the company stated: second quarter of 2027

    remains on track for a 12-month pivotal data readout in the second quarter of 2027

    ClinicalTrials.gov NCT05926765 · NCT stated in SEC filing

    SEC Form 10-Q · Filed: · Accession: 0001104659-26-095504 · Last checked: · Matched

    Earlier SEC statements (2)
    1. · “the 12 month pivotal data readout on track for the second quarter of 2027” · SEC filing
    2. · “the 12-month pivotal data readout on track for the second quarter of 2027” · SEC filing
  6. OCGNOcugen · OCU400NDA/BLA submission MatchedSEC ↗Watch

    Period the company stated: by the second quarter of 2027

    the BLA submission by the second quarter of 2027.Details

    Ocugen, Inc. (OCGN) · OCU400

    Stage: Not stated

    Public float (as of ): $279M (SEC filing) · Under $500M

    Period the company stated: by the second quarter of 2027

    We expect to begin a rolling BLA submission in the third quarter of 2026 and plan to complete the BLA submission by the second quarter of 2027.

    SEC Form 10-Q · Filed: · Accession: 0001628280-26-032454 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “The Company plans to initiate the rolling BLA submission for OCU400 in the third quarter of 2026 and complete the BLA submission by the second quarter of 2027.” · SEC filing
  7. OCGNOcugen · OCU410STTopline/data readout MatchedSEC ↗Watch

    Period the company stated: second quarter of 2027

    results anticipated in the second quarter of 2027, with a BLA submission to follow mid-2027Details

    Ocugen, Inc. (OCGN) · OCU410ST

    Stage: Not stated

    Public float (as of ): $279M (SEC filing) · Under $500M

    Period the company stated: second quarter of 2027

    Topline results anticipated in the second quarter of 2027, with a BLA submission to follow mid-2027

    SEC Form 8-K · Filed: · Accession: 0001104659-26-091691 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “Topline results are expected in the second quarter of 2027 with the BLA submission by mid-2027.” · SEC filing
  8. PROKProKidney · rilparencelTopline/data readout MatchedSEC ↗Watch

    Period the company stated: second quarter of 2027

    (eGFR slope) in the second quarter of 2027 and anticipate topline data readout of theDetails

    PROKIDNEY CORP. (PROK) · rilparencel

    Stage: Not stated

    Public float (as of ): $58M (SEC filing) · Under $500M

    Period the company stated: second quarter of 2027

    We anticipate topline data readout of the surrogate endpoint (eGFR slope) in the second quarter of 2027 and anticipate topline data readout of the confirmatory endpoint (composite time-to-event) in the second half of 2029.

    SEC Form 10-Q · Filed: · Accession: 0001193125-26-342373 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “The Company is on track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis in mid-2026, with pivotal topline results anticipated in Q2 2027.” · SEC filing

Window ends in: H2 2026

Grouped by the period end. The company's wording is retained in each row; no countdown is shown.

  1. ACRSAclaris Therapeutics · ATI-052Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    studies expected in the second half of 2026.Details

    Aclaris Therapeutics, Inc. (ACRS) · ATI-052

    Stage: Phase 1SEC filing · “Phase 1b; Phase 1b”

    Public float (as of ): $149M (SEC filing) · Under $500M

    Period the company stated: second half of 2026

    We initiated a Phase 1b proof-of-concept trial with ATI-052 in atopic dermatitis in January 2026 and a Phase 1b proof-of-concept trial in asthma in February 2026, with top-line data from both studies expected in the second half of 2026.

    SEC Form 10-Q · Filed: · Accession: 0001104659-26-092065 · Last checked: · Matched

    Earlier SEC statements (3)
    1. · “with top-line data from both studies expected in the second half of 2026.” · SEC filing
    2. · “with top-line data from both studies expected in the second half of 2026.” · SEC filing
    3. · “with top-line results from both trials expected in the second half of 2026.” · SEC filing
  2. AGIOAgios Pharmaceuticals · AG-181Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    trial are expected in the second half of 2026.Details

    AGIOS PHARMACEUTICALS, INC. (AGIO) · AG-181

    Stage: Not stated

    Public float (as of ): $1.9B (SEC filing) · $500M–$2B

    Period the company stated: second half of 2026

    Data from this trial are expected in the second half of 2026.

    SEC Form 8-K · Filed: · Accession: 0001439222-26-000115 · Last checked: · Matched

  3. ALMSAlumis · envudeucitinibTopline/data readout MatchedSEC ↗Watch

    Period the company stated: 2H 2026

    2, two-year safety data (2H 2026)Details

    ALUMIS INC. (ALMS) · envudeucitinib

    Stage: Phase 2SEC filing · “Phase 2”

    Public float (as of ): $183M (SEC filing) · Under $500M

    Period the company stated: 2H 2026

    Envudeucitinib in Moderate-to-Severe Plaque Psoriasis o Long-term data: Phase 2, two-year safety data (2H 2026)

    SEC Form 8-K · Filed: · Accession: 0001847367-26-000016 · Last checked: · Matched

  4. ALNYAlnylam Pharmaceuticals · ALN-6400Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    clinical trial in HHT the second half of 2026Details

    ALNYLAM PHARMACEUTICALS, INC. (ALNY) · ALN-6400

    Stage: OtherSEC filing · “Phase 1; Phase 2”

    Public float (as of ): $42.6B (SEC filing) · Over $2B

    Period the company stated: second half of 2026

    additional data from the Phase 1 clinical trial as well as initial results in the Phase 2 clinical trial in HHT the second half of 2026

    SEC Form 10-Q · Filed: · Accession: 0001178670-26-000062 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “additional data from the Phase 1 clinical trial as well as report clinical proof of concept in HHT in the second half of 2026” · SEC filing
  5. ALNYAlnylam Pharmaceuticals · ALN-6400Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    clinical trial in HHT the second half of 2026Details

    ALNYLAM PHARMACEUTICALS, INC. (ALNY) · ALN-6400

    Stage: Phase 2SEC filing · “Phase 2”

    Public float (as of ): $42.6B (SEC filing) · Over $2B

    Period the company stated: second half of 2026

    initial results in the Phase 2 clinical trial in HHT the second half of 2026

    SEC Form 10-Q · Filed: · Accession: 0001178670-26-000062 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “Phase 2 clinical trial in patients with HHT, and we plan to share additional data from the Phase 1 clinical trial as well as report clinical proof of concept in HHT in the second half of 2026” · SEC filing
  6. ALNYAlnylam Pharmaceuticals · ALN-2232Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    In the second half of 2026, Alnylam expects to announce clinical data from additional pipelineDetails

    ALNYLAM PHARMACEUTICALS, INC. (ALNY) · ALN-2232

    Stage: OtherSEC filing · “Phase 1 and Phase 2; Phase 1”

    Public float (as of ): $42.6B (SEC filing) · Over $2B

    Period the company stated: second half of 2026

    In the second half of 2026, Alnylam expects to announce clinical data from additional pipeline programs, including: • Results from Phase 1 and Phase 2 clinical trials of ALN-6400 in healthy volunteers and patients with hereditary hemorrhagic telangiectasia (HHT), respectively. • Results from a Phase 1 clinical trial of ALN-2232 in obesity and weight management.

    SEC Form 8-K · Filed: · Accession: 0001178670-26-000060 · Last checked: · Matched

  7. ALNYAlnylam Pharmaceuticals · ALN-HTT02Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    from this trial in the second half of 2026.Details

    ALNYLAM PHARMACEUTICALS, INC. (ALNY) · ALN-HTT02

    Stage: Phase 1SEC filing · “Phase 1b”

    Public float (as of ): $42.6B (SEC filing) · Over $2B

    Period the company stated: second half of 2026

    initiated a Phase 1b clinical trial of ALN-HTT02 in adult patients with HD and expect to present initial data from this trial in the second half of 2026.

    SEC Form 10-Q · Filed: · Accession: 0001178670-26-000062 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “initiated a Phase 1b clinical trial of ALN-HTT02 in adult patients with HD (NCT06585449) and expect to present initial data from this trial in the second half of 2026.” · SEC filing
  8. ARVNArvinas · ARV-393Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    a medical congress in the second half of 2026Details

    ARVINAS, INC. (ARVN) · ARV-393

    Stage: Phase 1SEC filing · “Phase 1”

    Public float (as of ): $469M (SEC filing) · Under $500M

    Period the company stated: second half of 2026

    clinical data from the early monotherapy cohorts in the ongoing Phase 1 dose escalation clinical trial of ARV-393 in patients with relapsed/refractory NHL at a medical congress in the second half of 2026

    SEC Form 10-Q · Filed: · Accession: 0001628280-26-052554 · Last checked: · Matched

  9. ARVNArvinas · ARV-806Topline/data readout MatchedSEC ↗Watch

    Period the company stated: second half of 2026

    clinical trial in the second half of 2026Details

    ARVINAS, INC. (ARVN) · ARV-806

    Stage: Phase 1SEC filing · “Phase 1”

    Public float (as of ): $469M (SEC filing) · Under $500M

    Period the company stated: second half of 2026

    KRAS G12D mutations. ◦ Reiterated plan to share initial data from the Phase 1 monotherapy dose escalation clinical trial in the second half of 2026

    SEC Form EX-99.1 · Filed: · Accession: 0001628280-26-052139 · Last checked: · Matched

    Earlier SEC statements (2)
    1. · “initial clinical data in patients with solid tumors harboring KRAS G12D mutations in 2026” · SEC filing
    2. · “initial clinical data i n patients with solid tumors harboring KRAS G12D mutations in 2026” · SEC filing
  10. AVBPArriVent BioPharma · firmonertinibTopline/data readout MatchedSEC ↗Watch

    Period the company stated: 2H 2026

    NSCLC is anticipated in 2H 2026.Details

    ArriVent BioPharma, Inc. (AVBP) · firmonertinib

    Stage: Phase 3SEC filing · “Phase 3”

    Public float (as of ): $762M (SEC filing) · $500M–$2B

    Period the company stated: 2H 2026

    EGFR exon 20 insertion mutant NSCLC is anticipated in 2H 2026.

    ClinicalTrials.gov NCT05607550 · NCT stated in SEC filing

    SEC Form 8-K · Filed: · Accession: 0001104659-26-094869 · Last checked: · Matched

  11. BHVNBiohaven · Opakalim (BHV-7000)Topline/data readout MatchedSEC ↗Watch

    Period the company stated: the second half of 2026

    to be on timelines for the second half of 2026.Details

    Biohaven Ltd. (BHVN) · Opakalim (BHV-7000)

    Stage: OtherSEC filing · “Phase 2/3”

    Public float (as of ): $1.0B (SEC filing) · $500M–$2B

    Period the company stated: the second half of 2026

    Dosing remains ongoing in BHV7000-303 and topline data continues to be on timelines for the second half of 2026.

    SEC Form 8-K · Filed: · Accession: 0001935979-26-000077 · Last checked: · Matched

    Earlier SEC statements (13)
    1. · “with topline results from the RISE3 trial expected in 2H 2026.” · SEC filing
    2. · “with RISE3 trial topline results expected in 2H 2026.” · SEC filing
    3. · “pivotal readout on track for 2H 2026” · SEC filing
    4. · “Topline results from the Phase 2/3 RISE3 trial in focal epilepsy remain on track for 2H 2026.” · SEC filing
    5. · “Topline results from the Phase 2/3 RISE3 trial in focal epilepsy are expected during 2H 2026.” · SEC filing
    6. · “study expected in 2H 2026.” · SEC filing
    7. · “We expect to report topline results from RISE 3 in the second half of 2026.” · SEC filing
    8. · “On track to receive top-line results in 2H 2026” · SEC filing
    9. · “Biohaven is on track to announce in 2H 2026 top-line results” · SEC filing
    10. · “We expect to report topline results from RISE 3 in the second half of 2026.” · SEC filing
    11. · “Pivotal epilepsy program with selective Kv7 ion channel activator, opakalim, with expected topline results in 2H 2026.” · SEC filing
    12. · “In the second half of 2026, we expect to report pivotal data from our epilepsy program and topline results from our obesity program” · SEC filing
    13. · “study expected in 2H 2026.” · SEC filing
  12. BHVNBiohaven · Taldefgrobep alfaTopline/data readout MatchedSEC ↗Watch

    Period the company stated: 2H 2026

    data expected during 2H 2026.Details

    Biohaven Ltd. (BHVN) · Taldefgrobep alfa

    Stage: Not stated

    Public float (as of ): $1.0B (SEC filing) · $500M–$2B

    Period the company stated: 2H 2026

    Topline data expected during 2H 2026.

    SEC Form 8-K · Filed: · Accession: 0001935979-26-000067 · Last checked: · Matched

    Earlier SEC statements (5)
    1. · “Topline results for the Phase 2 proof-of-concept study are expected in the second half of 2026.” · SEC filing
    2. · “taldefgrobep alfa, completed enrollment and topline data expected in 2H 2026.” · SEC filing
    3. · “In the second half of 2026, we expect to report pivotal data from our epilepsy program and topline results from our obesity program” · SEC filing
    4. · “Topline data from the study are expected in 2H 2026.” · SEC filing
    5. · “topline results expected in 2H 2026.” · SEC filing
  13. CHRSCoherus Oncology · tagmokitug + toripalimabTopline/data readout MatchedSEC ↗Watch

    Period the company stated: 2H 2026

    data readouts expected in 2H 2026.Details

    Coherus Oncology, Inc. (CHRS) · tagmokitug + toripalimab

    Stage: Phase 1SEC filing · “Phase 1b”

    Public float (as of ): $81M (SEC filing) · Under $500M

    Period the company stated: 2H 2026

    The Phase 1b dose-optimization studies evaluating tagmokitug in combination with toripalimab in second-line head and neck squamous cell carcinoma (HNSCC) and upper gastrointestinal adenocarcinomas remain ongoing, with initial data readouts expected in 2H 2026.

    SEC Form 8-K · Filed: · Accession: 0001104659-26-091188 · Last checked: · Matched

    Earlier SEC statements (1)
    1. · “● The Phase 1b tagmokitug/toripalimab combination dose optimization studies in 2L HNSCC and 2L upper GI adenocarcinoma cancers are underway, with initial data readouts expected in mid-2026.” · SEC filing
About this calendar
Calendar

FDA dates and trial readouts as each company stated them, with SEC original links. 250 programs as of . Free, with no sign-in. No forecasts, prices or signals.

Add to Google Calendar Apple Calendar The subscription follows the filters chosen here. No sign-up; ORION stores nothing about subscribers.

How this calendar is made
  • Entries are grouped by their retained period length: a date (with its count of days), a month (counted to its last day), then a quarter, half or year with no count. Period headings describe the window end; each row retains the company's exact wording. A date is the target action date the company stated.
  • Company size is the public float (market value of shares held by non-affiliates) on the company’s latest cover, with its reference date and SEC link. It does not decide which programs are listed.
  • Stage repeats the SEC filing or ClinicalTrials.gov registration wording. Without supporting wording, it is Not stated. Mixed phases retain their exact wording beside the source link.
  • Medicine research links use an NCT number stated in the SEC filing or company announcement, or a ClinicalTrials.gov match with sponsor, medicine and phase evidence. A registry match is labelled “matched by ORION (not stated in the filing)”.
  • Rows link to the program or company page. For a stated date, month, quarter, half or year, the period ends on its calendar end. Ambiguous qualifiers retain their wording without inferred endpoints.
  • Ambiguous periods and events without a date retain the literal wording in a separate section. No calendar date or countdown is created; these records are excluded from calendar subscriptions.
  • Active windows have no resolution filing held and end on or after today (UTC). A row with resolution evidence is shown in Results disclosed. Other rows move to Window ended after the stated period ends. Earlier wording and filing links remain available.
  • Event types distinguish trial data, enrollment completion, site activation and event-based analysis. Financial results and FDA meetings have their own filters. Audit status remains in the SEC wording. The type follows the SEC wording.
  • Displayed items need a true public-display field and a matching SEC quote and timing proof. Machine extraction does not add a founder review.
  • “Wording changed” opens the earlier sentences, each with its date and filing.
  • No forecast, price, score or signal. The calendar repeats what companies wrote.

Want an email when one of these changes? Get a free Watch.

All companies A–Z

A PDUFA date is the target date by which the FDA aims to decide on a drug or biologic application.A Form 10-K is a company’s annual report to the SEC, with audited financial statements.